Sign in
Taking people in United StatesPhase 2

Tests magnesium against saline during cancer surgery with cisplatin

Tests magnesium against saline in adults with mesothelioma receiving cisplatin during surgery.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Status
Recruiting
Phase
Phase 2
People taking part
130 people, planned
Started
4 Apr 2023
Expected to end
1 Jan 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Magnesium sulfate
  • Normal Saline
Record updated
21 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with malignant mesothelioma who are having surgery with heated chemotherapy (HIOC) given with cisplatin. It tests whether extra magnesium protects the kidneys.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Malignant mesothelioma, with surgery planned that includes HIOC.

Main reasons for not taking part

  • Kidney function eGFR below 45 ml/min/1.73m2, or end-stage kidney disease treated with dialysis or similar
  • Blood magnesium above 3 mg/dl
  • Pregnant or breastfeeding
  • Neuromuscular disease, such as myasthenia gravis or multiple sclerosis
  • Coronary artery disease in the past year, or a slow heart rate (below 55 beats per minute) or high grade heart block without a pacemaker

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • • Adult patients (≥18 years old) with malignant mesothelioma undergoing surgery with HIOC with Dr. Raphael Bueno or another BWH thoracic surgeon

Who cannot take part

  • Coronary artery disease, defined as any of the following in the prior year: a positive stress test; coronary angiogram indicating 1 or more vessels with >70% stenosis; percutaneous coronary intervention with stents; or coronary artery bypass graft surgery
  • Positive COVID test in the 10 days prior to surgery
  • Concurrent participation in a study with an alternative experimental therapy that may interact with IV Mg
  • Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myositis)
  • Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months
  • Hypersensitivity to Mg sulfate
  • Any condition that, in the view of the PI, might place the patient at increased risk or compromise the integrity of the study
  • eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Screening labs refer to those obtained at the preoperative visit with the surgeon or within 90 days prior, whereas preoperative labs are obtained on the day of admission (typically one to three days priors to surgery)
  • Serum Mg >3 mg/dl on either screening labs or preoperative labs
  • Pregnant/breastfeeding
  • High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker
  • Prisoner
  • Conflict with other study

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Shruti GuptaTaking people

About the trial

What the trial wants to find out

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo

Read full original descriptionShow less

.

The 2 groups in the trial

  • Magnesium SulfateTreatment being tested

    The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).

  • Normal SalinePlacebo, for comparison

    Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
Plain-language title
Tests magnesium against saline during cancer surgery with cisplatinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 November 2025